Drug intelligence / Profile preview

cordyceps sinensis

Development stage
Phase 4
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Cordyceps sinensis is a parasitic medicinal fungus traditionally used in Chinese medicine for centuries. It grows on the larvae of certain moths and is highly valued for its purported health benefits. The main bioactive compounds include cordycepin (3-deoxyadenosine), polysaccharides, and d-mannitol. Cordyceps sinensis has been studied for its anti-inflammatory, antioxidant, immunomodulatory, antitumor, anti-aging, and adaptogenic properties[2][5][6]. Mechanistically, it appears to modulate immune responses by enhancing natural killer cell activity and propagating helper T cells; it also exhibits effects on energy metabolism (possibly increasing ATP production), supports kidney function (notably in chronic kidney disease), improves respiratory function by enhancing oxygen utilization during exercise or illness[5][7], may lower blood sugar levels via insulin modulation[6], and shows potential cardiovascular benefits such as lowering LDL cholesterol and triglycerides[6]. While animal studies are promising regarding inflammation reduction (e.g., arthritis models) and improved aerobic performance or fatigue resistance in humans[2][4], robust clinical evidence remains limited. Cordyceps sinensis is difficult to harvest naturally; most supplements use cultivated strains like CS-4 due to cost constraints[2].

Other names
dong chong xia caochinese caterpillar funguswinter-worm summer-grass蛹虫草菌粉
02

Targets

CD4 (T lymphocyte surface antigen)IL-6 (Interleukin 6)EGFR T790M (Epidermal growth factor receptor T790M mutant)ADK (Adenosine kinase)CAT (Catalase)RNAP (Bacterial dna-dependent RNA polymerase)CASP3 (Caspase-3)

Beyond the preview

Go deeper on cordyceps sinensis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cordyceps sinensis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call